Videos

brightcove ad test

Articles

The Latest in Testosterone Replacement Therapy

Karen Nash is a medical reporter and media consultant based in Monroeville, PA.

"I prefer doing transvaginal prolapse surgery with native tissue and always have. So I was not affected when mesh was restricted," says one urologist.

How has the FDA’s mesh guidance affected POP treatment?

In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.

Dr. Lemack on treatments in development for OAB

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.

MOSES-enabled pulsed laser allows same-day discharge without catheter

Patients using anticholinergic medications for the management of overactive bladder (OAB) are at increased risk of new-onset dementia compared with individuals treated with the beta-3 agonist mirabegron (Myrbetriq), according to findings of a new population-based, retrospective study published online March 13, 2020, in BJU International.

Study adds to evidence linking anticholinergics, dementia

"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.

New developments may change treatment of OAB

Unhealthy eating, like that associated with the Western diet, is associated with notably worse semen quality and less favorable testicular function than healthier eating patterns, according to a study of nearly 3,000 young Danish men published in JAMA Network Open (2020; 3:e1921610).

Unhealthy diet associated with poor semen quality

The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

FDA accepts new drug application for overactive bladder agent

Kerr is group content director for Urology Times.

All News